Biocon’s shares soared 5% on Tuesday, December 24, closing at ₹344.80 after hitting an intraday high of ₹347.35. The rally was fueled by two significant developments that strengthened investor confidence in the company’s growth trajectory. The first boost came from the United States Food and Drug Administration (USFDA), which issued an Establishment Inspection Report (EIR) with a Voluntary Action Indicated (VAI) status for Biocon’s Active Pharmaceutical Ingredients (API) facility in Bengaluru. Adding further momentum, Biocon announced that its European partner, Zentiva, received a decentralised procedure approval in the European Union (EU) for Liraglutide, a complex formulation used to treat Type-2 diabetes and manage weight. Biocon’s stock, which has already gained 35% year-to-date, reflected the optimism around these developments. The Bengaluru-based biopharma giant is clearly on a roll, leveraging strategic partnerships and regulatory approvals to solidify its presence in both the API and biosimilar markets.